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The aim of this work is to review the most important topics about the antiophidic sera sterility, including 
obtaining methods, sterilization procedures and clean room control using Vital Brazil Institute (VBI) 
as an example. Bibliographical research was performed through Medline, Lilacs, PubMed, ISI and the 
Fundação Oswaldo Cruz - RJ and VBI Libraries, from 1960 to 2009. The antiophidic sera for human use 
are immunobiologic products produced in Brazil by three national laboratories, including VBI. Due to 
the parenteral use, these products should be sterile and pyrogen-free, which demands the microbiological 
control during the whole fabrication process. The sterility and pyrogen tests are important steps to ensure 
the quality and safety of these immunobiological products. Thus, these tests are target for continue 
evaluation and improvement. The most interfering aspects in the consistency and analytical patterns 
include the proper method selection, sampling, culture conditions and validation criteria. As the national 
and international legal requirements are cautious with the assays validation and approval of sterile 
parenteral products; the intrinsic limitations for established assays still require more investigation aiming 
the continue improvement of the microorganism and contaminants detection methods and optimization 
of the analysis extent.
Uniterms: Microbiologic control. Antiophidic sera. Sterility test. Contaminants. 
O objetivo deste trabalho é revisar os tópicos mais relevantes para o controle da esterilidade de soros 
antiofídicos, abordando-se métodos de obtenção, procedimentos de esterilização e o controle de áreas 
limpas utilizando como exemplo os procedimentos adotados pelo Instituto Vital Brazil (IVB). Um 
levantamento bibliográfico foi realizado no Medline, ISI, Biblioteca da Fundação Oswaldo Cruz-RJ e 
IVB, no período de 1960 a 2009. Os soros antiofídicos para uso humano são produtos imunobiológicos 
fabricados no Brasil por três laboratórios nacionais, dentre eles o IVB. Por serem de administração 
parenteral, devem ser obrigatoriamente estéreis e apirogênicos, exigindo controle microbiológico durante 
todo o processo de fabricação. O teste de esterilidade e apirogenia são importantes instrumentos para 
garantir a qualidade e segurança microbiológica desses produtos, sendo alvo de avaliações constantes para 
seus aprimoramentos. Os aspectos que mais interferem na sua consistência e valor analítico incluem a 
escolha adequada do método, amostragem, condições de cultivo e critérios de validação. À medida que os 
requisitos legais nacionais e internacionais se mostram rigorosos na validação de ensaios e aprovação de 
produtos estéreis parenterais, limitações intrínsecas ao ensaio padronizado requisitam mais investigações, 
objetivando o aprimoramento contínuo nos métodos de detecção de microorganisms, contaminantes e 
otimização do tempo total de análise. 
Unitermos: Controle microbiológico. Soros antiofídicos. Teste de esterilidade. Contaminantes.
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INTRODUCTION
Brazil is one of the countries that are pioneers in the 
treatment of the envenomation caused by snake venom. 
According to the Brazilian Health Ministry, snakes are 
responsible for about 20,000 accidents per year with 100 
deaths (FUNASA/MS, 1998).
The antiophidic sera used for treating these patients 
are immunobiological products for subcutaneous or sub-
mucous injections use. Among several requirements, these 
products must be microorganism and endotoxin free, whi-
ch may be obtained through a rigid microbiologic control 
during the whole fabrication process (Brasil, 2005; United 
States Pharmacopeia, 2008)
The general sterility concept refers to total absence 
of organisms capable of reproduction (Runkle, Phillips, 
1969). However, due to the current statistical knowledge 
about microorganism death, there are some questions 
about product sterility concepts. The sterility processes 
follow the criteria of logarithmic reduction of the con-
taminant amount in the product. Despite of that, it is not 
possible to assure the complete removal of all forms of 
contamination.
The most applicable probabilistic concept suggests 
that the lowest probability of the microbial presence is 
achieved when it is smaller than 10-6, which assures the 
sterility condition of the product. As a consequence, the 
expression “living form-free” has been used instead of 
sterile (Bugno, 2001; Luqueta, 2003).
In order to evaluate the analytical significance of 
the sterility test, it is necessary to understand the intrinsic 
problems of microbiological detection in the assays as 
well as the difficulties on sampling, since it should assure 
the statistical significance in terms of batch size (Pinto, 
Kanako, Ohara, 2003). 
According to the current Pharmacopeia accepted 
by National Agency of Health Surveillance of Brazil 
(Brasil, 2003), the sterility condition of a product requires 
optimal processing conditions under Good Manufactu-
ring Practices (GMP), and absence of microbial growth 
in appropriate culture media of a statistically significant 
sample(Brazilian Pharmacopeia, 1988; European Phar-
macopoeia, 2007; British Pharmacopoeia, 2008; United 
States Pharmacopeia, 2008).
The products without evident alterations may also 
contain microbial contamination. In immunocompetent 
adults, the contact with contaminated products may not 
represent a serious problem, unless in case of the: a) mi-
croorganism is a primary pathogen, b) microbial burden 
is elevated or c) product is for inoculation in areas such 
as blood vessels, injured skin, mucosa or eyes. The risk 
is higher when it involves an immunodepressed patient 
(Denyer, Baird, 2006).
Therefore, the risk of infection depends on factors 
such as qualitative and quantitative characteristics of the 
microorganisms, host resistance and administration root. 
In general, the presence of non-pathogenic microorganism 
is allowed for products of oral or topic use in a limited 
amount, if the resistance is maintained inside the validity 
period (Hinrichsen, 2004). Differently, for the parenteral 
products, such as antiophidic sera, the risk of infection 
must be strictly controlled concerning the contaminant 
presence by using sterility and endotoxin detection tests.
Due to the importance of the microbiological control 
in the antiophidic sera production process and its influence 
in these products quality evaluation, the aim of this review 
is to identify the most important aspects of manufacturing 
and controlling living form-free products through GMP. 
On that purpose we searched specialized bibliographies 
and legal sources (legislations and Pharmacopeia) also 
approaching concepts about parametric release proposed 
by ANVISA in courses and routine inspections. 
Sterile parenteral solution manufacturing
The manufacturing of sterile liquid products is divi-
ded into three groups, including those submitted to (i) final 
sterilization (the product is already in the primary flask) by 
using thermal (autoclave or dry heat), chemical (ethylene 
oxide) or irradiation methods; (ii) aseptic manipulation; 
and (iii) proper filtration process as a sterilizing step. In 
the last two groups, the product is exposed to potential 
contamination sources at the end of the process (Brazilian 
Pharmacopeia, 1988).
In pharmaceutical industry, the final sterilization 
process is always a selective procedure, especially the use 
of autoclavation, in which the compatibility between the 
nature of the product and the sterilizing agent should be 
confirmed (Hinrichsen, 2004).
The microbiological contamination or bioburden of 
a sterile medicament production must be sufficiently redu-
ced (~100 UFC/mL or g) prior to the sterilization process 
to reduce the endotoxins formation, especially pyrogens. 
In a manufacturing process, all solutions must be submit-
ted to a sterilizing filtration prior to the filling process and 
sterilization in their final recipients, preferentially by using 
wet heat if the carried drug is thermal-resistant. The wet 
heat sterilization led to the coagulation and denaturation 
of microorganisms essential proteins and enzymes. The 
autoclavation is an effective and safe wet heat sterilization 
procedure and the most used sterilization method in the 
industry (Hinrichsen, 2004; Trabulsi, Alterthum, 2005; 
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Brazilian Pharmacopeia, 1988; European Pharmacopoeia, 
2007; British Pharmacopoeia, 2008; United States Phar-
macopeia, 2008).
As some pharmaceutical formulations may not be 
sterilized in its final recipient, they must be submitted to 
a sterilization filtering process or to an aseptic manipula-
tion. The sterilizing filtration aims to physically remove 
microorganisms, particulate gas and liquid materials, 
excluding bigger particles or adsorpting particles smaller 
than the filter pore (0.22 to 0.10 μm). Different filtering 
materials are commercialized such as polycarbonate or 
cellulose derived (nitrate and acetate) matrixes in mem-
branes cartridge forms. 
Some antiophidic sera suffer unacceptable degra-
dation under heat, and need an alternative method of 
sterilization for heat-labile pharmaceutical products. The-
refore, a strictly control of the sterilization process must 
be employed including: a) filtering elements integrity test, 
b) rigorous control of cleaning and manufacturing envi-
ronment air quality, and c) monitoring of air-suspended 
particle concentration (Brazilian Pharmacopeia, 1988; 
European Pharmacopoeia, 2007; British Pharmacopoeia, 
2008; United States Pharmacopoeia, 2008).
Microbial resistance to inactivation
A sterilization process model must be related to the 
bioburden and to the microorganism inactivation kinetics 
when exposed to a lethal agent (Luqueta, 2003). Several 
mathematical models have been developed to help on the 
Sterility Assurance Level (ASL) calculation, quantifying 
the bacterial inactivation. Among the most used methods 
is the microbial inactivation rate constant (k), which deter-
mines the inactivation rate as direct related to the number 
of organisms during a period of time. Thus, each exposure 
to the lethal agent leads to the inactivation of part of the 
surviving population. Another important value is the deci-
mal reduction (D) value that is the exposure time required 
to alter a surviving population by 10, or the required time 
for observing one log reduction on the survival rate. 
As D and k values measure the resistance of a micro-
organism to a specific inactivation process, both are used 
in pharmaceutical industry as comparative parameters 
for validation of sterilization processes and selection for 
using in parametric release form of the sterile final product 
(Vessoni Penna, 1994; Vessoni Penna, Machoshvili, 1997). 
Resistance to physical or chemical agents used in the 
sterilization processes are due to many factors including: 
(i) some genetic-determined microorganism characteris-
tics (i.e. sporulated or unsporulated bacteria); (ii) environ-
mental parameters; (iii) temperature; (iv) nutrient pH; and 
(v) microorganism growth time or phase (generally more 
susceptible to inactivation at log phase); (vi) the presence 
of components such as carbohydrates, lipids, proteins, 
and (vii) the pharmaceutical formulation. In fact, each 
sterilization process requires optimization to ensure ASL 
(Vessoni Penna, 1994; Ishisaki, 1998).
Bacteria spores are generally considered as the most 
resistant form to sterilization processes, despite of their 
differences. Most viruses have resistance similar to the ve-
getative form of bacteria and yeasts. Literature shows that 
some viruses such as the poliovirus and hepatitis B virus 
present major resistance to inactivation, similar to prions 
(proteinic aggregates involved in infectious diseases). 
However, prions are an exception and therefore are not 
used as reference for sterilizing processes. Fungi spores 
are generally more sensitive to inactivation if compared 
to bacterial spores (Luqueta, 2003; Denyer, Baird, 2006). 
This consideration is more relevant for products of biolo-
gical origin, such as sera or vaccines, than to traditional 
pharmaceutical preparations. The determination of the 
contaminating flora in the local of the manufacturing is 
of great importance for preventing severe contamination 
problems of the biological products, including antiophidic 
sera. 
Sterilizing process-resistant microorganisms require 
the qualification of the selected sterilizing cycles. The 
use of reference-strain (bioindicators) protocols are com-
monly developed using preferentially sporulated forms. 
Formulations containing synthetic drugs use the Bacillus 
stearothermophilus ATCC 7953 as reference bioindicators 
in final wet heat sterilization, as well as B. subtillis ATCC 
9372 in dry heat and ethylene oxide sterilizations, and B. 
pumillus ATCC 27142 spores in irradiation sterilization. 
Pseudomonas diminuta ATCC 19146 (or Serratia mar-
cescens and Chromobacterium prodigiosum according to 
Brazilian Pharmacopeia) is the reference bioindicator for 
the validation of filtering sterilization. P. diminuta also 
serve as a parameter to evaluate the effective retention 
of the microorganism cells with size compatible to the 
filtering element nominal pore size, especially the micro-
organisms that suffer no size reduction when in contact 
to pharmaceutical preparations (Madsen, Akers, Jornitz, 
2006; Brazilian Pharmacopeia, 1988; European Pharmaco-
poeia, 2007; British Pharmacopoeia, 2008; United States 
Pharmacopeia, 2008). 
However, sometimes based on medicine producers’ 
initiative, no bioindicators are used in thermal or chemical 
sterilization processes due to the insertion of a contamina-
tion source inside a rigorous quality control factory envi-
ronment. The situation is more severe in the production of 
an antiserum or other immunobiological products, where 
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the insertion of bioindicators in the process is unaccepted. 
It is important to notice that bioindicators are used in the 
industry pharmaceutical routine only for thermal-sterili-
zation process. Meanwhile, the filtering element integrity 
evaluation assay (i.e.; diffusive pressure or bubble point 
tests) remains for the sterilizing filtering process as a mi-
crobiological challenge for the filtering element producer. 
The production of a pyrogen-free formulation 
is also another issue for those of parenteral use. The 
gram-negative bacteria lipopolysaccharides are the main 
pyrogens evaluated in the quality control of the injectable 
producing industry, as they are not inactivated by wet heat 
sterilizing methods (Pinto, Kanako, Ohara, 2003). Besides, 
the methods using heat (dry or wet) are not considered for 
sterilizing antiophidic sera as they cause their inactivation. 
Therefore, the use of porosity filtering, absorption and ste-
rile manipulation demand strict control in terms of sterility 
and pyrogenicity assessment.
Antiophidic sera obtaining processes and 
microbiological control
Antiophidic sera are sterile immunobiological pro-
ducts used in therapy against snake envenomation. They 
are produced by using health horses immunized with a 
mixture of representative snake venoms of each region. 
Antiophidic sera specifically neutralize the toxic venom 
compounds of one or more snake species (Vital Brasil 
Institute, 2006b).
For antisera production, six liters of blood from 
hyperimmunized horses are conditioned in sterile bags 
with anticoagulant, at 2 to 8 ºC, for sedimentation of the 
red blood cells. After plasma obtaining, the red blood cells 
are reinserted into the animals. Then the plasma is sub-
mitted to enzymatic treatment, fractionated precipitation 
and molecular cutoff ultrafiltration to purify a high level 
of specific immunoglobulins (Brazilian Pharmacopeia, 
1988; British Pharmacopoeia, 2008).
Among the main purposes of a filtering process 
are the solution clarification and sterilization. Both are 
necessary during antiophidic sera production to guarantee 
the product quality. The clarification filtering to remove 
particles as small as 3.0 mm is used in the concentrated 
antisera step. After final dilution and phenol addition, 
the antisera are submitted to pre-filtering and sterilizing 
filtering, using 2.0 and 0.22 mm cartridges, to obtain the 
final product, the sterile antisera. After filling the flasks, 
the final product must be clear, colorless or slightly yellow, 
free of microbial contaminants and particles or aggregates 
(United States Pharmacopeia, 2008). 
To ensure the quality of sterile products such as 
the national laboratory produced antiophidic sera, the 
resolution number 176 of 1996 from ANVISA/MS and 
Brazilian Pharmacopeia from 1988 (part 1, V.5) deter-
mine the performance of physical-chemical, biological 
(potency, unspecific toxicity and “in vivo” pyrogen) and 
microbiological tests of many steps products such as 
plasma, concentrated antisera and final antisera. In fact, 
regarding pyrogenicity, RDC 249 determines the specific 
endotoxins detection, indicating the importance of in vitro 
pyrogen tests to assure a pyrogen-free product (Brasil, 
2005). If the specifications are attended, the preparation 
is packed and tested once more by using a sample and the 
same parameters, including average volume. The control 
of the production conditions is fundamental to ensure final 
product quality since the characteristics of this product do 
not allow any other sterilization technique but filtering 
sterilization.
All production system should guarantee the suita-
bility of all installations, methods, processes, protocols 
and controls used in the fabrication steps of the active 
pharmaceutical material to ensure the final product quality. 
These control processes must follow the current legislation 
recommendations as well as to adapt to diverse fabrication 
processes (chemical, physical and/or biological). In fact 
these procedures may be updated to include the latest 
technological advances. 
The Good Manufacturing Practices (GMP) allied to 
Quality Insurance and Quality Control are important for 
the whole manufacturing process as they assure the final 
product identification, purity and safety requirements, ba-
sed in the pre-set quality policies. Each step has to follow 
GMP as well as guarantees all specific controls (Brasil, 
2003b; 2005).
The control quality tests performed in the final pro-
duct aim to certify the quality of each product lot concer-
ning to the physicochemical, biological and microbiolo-
gical patterns. In case of Vital Brazil Institute (VBI), if the 
product lot is approved, a sample is sent for re-testing and 
releasing for human use to the National Institute of Health 
Quality Control (INCQS) from Oswaldo Cruz Foundation 
(FIOCruz), a national reference lab specialized in immu-
nobiologic analysis (United States Pharmacopeia, 2008).
Importance of manufacturing control
Sterilization control and other process conditions are 
effective tools to ensure final product sterility. These tools 
are base of the parametric release with the main purpose 
of reducing the number of analysis performed, especially 
of the sterility test, to confirm the quality of the final 
pharmaceutical product. According to European Agency 
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for the Evaluation of Medicinal Products, the parametric 
release is the feasibility of ensuring the product quality, 
through the analysis of the information obtained during 
manufacture process under Good Manufacture Practices 
(Wilson, 1998).
Parametric release is not officially accepted by Bra-
zilian legislation, in contrast to United States, where FDA 
already supports it. Every product that should be sterilized 
by steam, dry heat or ionizing radiation in its final packing 
may be released based on the processes data instead of 
exclusively through sterility tests data, as long as these are 
validated processes.Parametric release is not an alternative 
to liberate the commercialization of products sterilized by 
filtration or aseptic packing, despite there is no restriction 
for using parametric release in technical point of view. In 
Brazilian legal terms it will be used only for increasing 
the guarantee of sterility and quality of a manufactured 
product lot, even under requirement for a final sterility as-
say. Compared to the process results, all physicochemical 
and biological data (preferentially obtained in real time) 
assure more safety than only the sterility test for both, final 
packing sterilized products or those differently sterilized 
(Wilson, 1998). Several requirements should be fulfilled 
to obtain FDA approval for using parametric release on 
parenteral products manufacturing including: 
ü	 Products submitted to final sterilization;
ü	 10-6 sterility assurance level (SAL);
ü	 Full sterilization cycle description;
ü	 Cycle qualification: heat distribution and penetration;
ü	 Minimal process parameters definition;
ü	 Determination of bioindicators thermal resistance;
ü	 Comparison of Bioindicators with bioburden;
ü	 Targeting packing and closing systems;
ü	 Full written protocol for the entire process;
ü	 Environmental monitoring program description;
ü	 Quantitative sterilization cycle monitoring;
ü	 No permission for administrative revisions such as 
authorizing product release that do not follow the 
parametric release specifications.
However, several evaluated aspects of the para-
metric release are not applicable in filtering sterilizing 
processes. As an alternative, basic points approached in 
the sterility warranty system may be used as support to 
confirm the sterility of a final product (Pharmaceutical 
Inspection Convention, 2004). They include:
ü	 Control of the microbiological contamination burden 
in the materials used in the process;
ü	 Control of the contamination of the manufacturing 
process, through cleaning and sanitization of the 
manufacturing area, to avoid microorganisms in 
product;
ü	 Control of the process during different process fil-
tering stages (bubble point and diffusive pressure 
tests);
ü	 Prevention of cross-contamination between sterile 
and non-sterile products;
ü	 Maintenance of product integrity (packing);
ü	 Test of the aseptic packaging;
ü	 Equipment qualification, calibration and maintenance.
In addition to that, the insertion of real time control 
on the manufacturing process based on Process Techno-
logy Analysis (PTA) of critical parameters reinforces the 
final product sterility assurance (FDA site guidance for 
industry). Each step of production should follow well 
established procedures with verification and registering 
of equipments, working area, documents, materials, do-
cuments and available materials (Brasil, 2005).
Controlled environments - clean rooms
The air is one of the most common causes of micro-
bial contamination, due to particles such as dust and skin 
cells that carry microorganisms and protect them from 
oxidation or desiccation (Halls, 2004). As low bioburden 
level is required prior to the autoclavation of final sterilized 
products, this is only feasible in an environment controlled 
in terms of: a) air, b) number of suspended particles, c) 
cleaning of the area, d) equipments and utensils, and e) 
workers performance. If a product is not compatible to 
autoclave sterilization and undergoes through sterilizing 
filtration or aseptic packaging, the rigorousness of control 
is even greater, and manufacture area is named clean room 
or area (Halls, 2004; Denyer, Baird, 2006).
In a non-controlled environment, it is common the 
formation of different particulate aerosols associated 
with microbial agents, which represents a significant 
level of contamination to the pharmaceutical processes 
(Halls, 2004; Moorfield, 2006). Current filtering and air 
renewal methods allow reaching the quality for a suitable 
environment, also considering the demands of the manu-
facturing critical steps and drug sterility test. RDC 210 of 
2003 defines clean room as “an area with the environment 
control defined in terms of viable and non viable particles 
contamination, designed, built and used to reduce the 
introduction, generation and retention of inner contami-
nants” (Brasil, 2003b).
According to international standards, the quality of 
the air present in the processing of sterile products in the 
pharmaceutical industries needs to fulfill strict require-
ments including: a) limited number of particles of 0.5 to 
5 μm, b) absence of particles higher than 5 μm, and c) air 
filtration (Moorfield, 2006). 
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The current technology allows the commercial pro-
duction of ultra-low particle arrestors (ULPA) air filters 
with 99.99996% efficiency for 0.12 μm particles. Filters 
presenting efficiency of 99.9997% for 0.3 μm particles 
(High Efficiency Particulate Air Filtration - HEPA) are 
appropriated even for pharmaceutical area restricted pur-
poses (Millipore, 2006). 
The most important structural characteristics of 
clean rooms include presence of horizontal or vertical 
laminar flow cabinets; directed air flow to avoid room 
turbulence; positive pressure compared to neighboring 
uncontrolled areas to avoid contamination; absence of 
irregularities in the surfaces to avoid particle depositing; 
and finally an filtrated air system with supply through the 
ceiling opposed to the exhaustion on the bottom of the 
room, possibly with a germicide lamp (Bugno, 2001; De-
nyer, Baird, 2006). Currently the pharmaceutical industries 
use isolators, which are sterilizable air-sealed chambers, 
which present HEPA filters. Thus the filtering process of 
all sterile products may be performed with an easier con-
tamination control, with an expectation of total absence 
of microorganisms (Pedroso, Allil, 1998).
The present legislation is limited when reporting 
about the standards parameters for clean rooms. Therefore, 
most of the sterile product producing and controlling orga-
nizations adopt US Federal Standard 209 (A and E), which 
establish the maximum particles amount (viable or non-
viable) per cubic feet, or in the most recent version (E), per 
cubic meter. In 1997, the ISO also created the standards for 
the areas classification of the clean room. The areas clas-
sified as ISO 3 to 8 are equivalent to 1 to 100,000 classes 
of US Federal Standard (USFS), respectively (Moorfield, 
2006). Table I shows the classification according to ISO 
and US Federal Standard 209 D and E revisions.
Finally, a new standard for GMP of sterile products 
established four classes, considering the particles amount 
of a resting or working room (Table II). The “resting” 
condition involves the complete installation with full 
equipments, but without the workers. The “working” si-
tuation indicates the room in the operational mode, with 
a number of workers.
The first class (A) corresponds to critical operation 
locations (i.e. packaging and aseptic connection manipu-
lation). The second class (B) is proper for environments 
close to those where the product is prepared and packaged. 
The values are close to those established by the ISO and 
US Federal Standard systems. Thus A and B are equivalent 
to classes 100, M 3.5 and ISO 5, and represent required 
areas for producing and controlling sterile products accor-
ding to RDC 210 (Brasil, 2003b).
The parameter involving the quality of the air pre-
sent in the clean area is added to others, when using the 
parametric release to enable the commercialization of a 
safer parenteral product of any volume. 
Antiophidic sera sterility test
Antiophidic sera sterility test aims to detect viable 
microorganisms on the evaluated product (Brazilian Phar-
macopeia, 1988). Over the years, this test is continually 
improved to increase microbiological quality and safety 
of sterile products. 
Despite the parenteral therapy was created in the 
last century, the first official method for the sterility test 
was reported in British Pharmacopoeia, in 1932. The 
regulation established the test for liquid form products 
and the use of peptone broth and 37 ºC incubation for 5 
days, for detecting aerobic bacteria. In 1936, the eleventh 
edition of United States Pharmacopoeia (USP) adopted 
TABLE I - Classification based on number of particles allowed 
per cubic meter, according to three different systems (United 
States Federal Standard - USFS) 
   







Maximum number of 
particles / m3
0.5 to 5 μm >5 μm
1 M1.5 3 35.3 NDb
10 M2.5 4 353 ND
100 M3.5 5 3,530 ND
1,000 M4.5 6 35,300 247
10,000 M5.5 7 353,000 2,470
100,000 M6.5 8 3,350,000 24,700
aSource: Moorfield, 2006. b Not defined.
TABLE II - Classification for sterile products manufacturing in 
accord to GMPa
Degree








A 3,500 0 3,500 0
B 3,500 0 350,000 2,000
C 350,000 2,000 3,500,000 20,000
D 3,500,000 20,000 ND NDb
a Source: WHO Technical report Series number 902, 2002. In: 
Brasil, 2003.
b Not defined.
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the same methodology. The analytical resource has been 
continually improved to allow detection of anaerobic and 
microaerophile microorganisms. 
In the thirteenth edition of USP, the test was exten-
ded to fungi detection, using honey containing culture 
medium and incubation at 22 to 25 ºC for 15 days. The in-
novation occurred in 1964, by officialization of the indirect 
sample inoculation (membrane filtration) method by the 
FDA, as an alternative to the direct inoculation method. In 
1970, USP introduced the membrane filtration technique, 
which was followed by the Brazilian Pharmacopeia in 
1976. After 1988, a longer incubation period of 14 days 
was established for direct and indirect methods (Pedroso, 
Allil, 1998; Bugno, 2001; Pinto, Kaneko, Ohara, 2003).
The improvement of the sterility test aims to assure 
the quality of the sterilizing process and of the sterile 
products considering the probabilistic and contamination 
risks. However this assay becomes extremely time-
consuming also increasing the production time, which is 
target of criticism. Thus it is necessary to evaluate when 
this procedure is essential or if it may be replaced by alter-
native approaches, such as the parametric release.
Sampling
The sterility test is a destructive assay that cannot 
be applied to the whole lot. Therefore, this test should be 
based on an essentially statistic sampling method where 
the number of samples to be tested should be representa-
tive of the whole lot. The results are determined based on 
the number of the selected samples and of the contamina-
tion level, aiming to safely extend these data to the entire 
lot (Peixoto, Oda, 1984a, b).
The sampling of the packaged products generally 
follows a proportionality within the lot. By the rule, 10-20 
unities of each parenteral product lot are selected, depen-
ding on the total volume of each pack or flask. In fact, 
the approval probability of a contaminated lot is reduced 
when the size of sample is increased (Pinto, Kanako, 
Ohara, 2003).
According to Peixoto and Oda (1984b), the data 
obtained from a sterility test performed with non-represen-
tative statistically samples may not be safely extended to 
the entire lot. This means that a significant small number 
only serves to detect a high level of contaminated unities. 
Therefore, the British, American and European Pharma-
copeias established a minimum number of unities to be 
selected and tested based on the lot size. For lots smaller 
than 100 unities, 10% or 4 unities (the higher value) should 
be tested whereas for lots between 100 and 500 unities, or 
higher than 500 unities, the selections are 10 unities, and 
2% or 20 unities (30 unities according to British Pharma-
copoeia) - the lowest value - respectively. The Brazilian 
Pharmacopeia establishes the test of at least 20 unities 
or 10% of lots smaller than 199 unities. According to the 
Brazilian Pharmacopeia, the proper sampling for raw 
material is based on the root square of the total number of 
recipients of the lot.
The filling volume of antiophidian sera (10mL) is 
bigger than those of some vaccines. According to the Bri-
tish and American Pharmacopeias the minimal amount of 
sampling of each antiophidian sera recipient is of 5 mL in 
contrast to European Pharmacopeias (2 mL). The Brazilian 
Pharmacopeia rules for injectable medication are shown 
in the Table III. 
Source: Adapted from Brazilian Pharmacopeia, 
1988. a For volumes higher than 100 mL, it is recommen-
ded the  membrane filtering method using the whole 
recipient volume.
Inoculation methods
Currently, the Brazilian, American, British and 
European Pharmacopeias indicate two culture medium 
inoculation forms mainly due to availability, feasibility, 
efficiency or economical limitations. 
Direct inoculation
In this method, samples products are inoculated 
in broth or solid culture medium, using pipette, syringe 
TABLE III - Correlation between the sample volumes and culture media in the direct and indirect (membrane filtering) methods
Total Volume of full 
recipient (mL)
Mínimal Volume of the 
product to be tested (mL)
Minimal Volume of the culture 
media (mL) Direct Method 
Minimal Volume of the culture 
media (mL) Filtering Method
< 10 1 mL, or full amount< 1mL 15 100a
11-50 5 40 100
51-100 10 80 100
Source: Adapted from Brazilian Pharmacopeia, 1988. a For volumes higher than 100 mL, it is recommended the membrane 
filtering method using the whole recipient volume.
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or direct spill, and are incubated for 14 days at proper 
temperature. Due to difficulties on performing filtering 
processes, this method is commonly used for suspended 
particles products or those with high density.
The advantages of direct inoculation method inclu-
de feasible and easy process that requires brief manipu-
lation and training, with low accidental contamination 
risks. In contrast, disadvantages are low representati-
veness of the sample volume, inhibitory agent residues 
(preservatives), restriction to large volumes, and risks of 
approving a contaminated lot (Fracalanzza, 2005; Vital 
Brasil Institute, 2006c).
Indirect inoculation (Filtering
It was developed in 1957 by Holdowsky and do-
cumented by FDA and United States Pharmacopoeia in 
1964 and 1970 respectively (Pedroso, Allil, 1998). The 
membrane filtration method is widely used in sterile pro-
ducts manufacturing industries. The Vital Brazil Institute 
uses this methodology for testing antiophidic sera during 
fabrication of bulk and packaged products.
The method consists of filtering a specific volume 
using a nitrocellulose membrane with hydrophobic bor-
der, 47 mm diameter and maximum nominal porosity of 
0.45 μm (or 0.22 μm) (Millipore, 2006). The 0.45 μm-
membrane allows the detection of microorganism in 
samples submitted to the sterility tests whereas the 
0.22 μm-membrane completely retains viable and non-
viable particles in both sterilizing filtering processes and 
sterility tests. The Vital Brazil Institute uses 0.22 μm-
membrane for sterility tests and sterilizing filtering 
processes (Vital Brazil Institute, 2005). 
The filtering system used in the indirect sterility test 
consists of a base supported receptacle, under a kitasato atta-
ched filtering membrane. The filtering process is performed 
under negative pressure using an oil free vacuum pump, and 
flow of 55 to 75 mL/min (Brazilian Pharmacopeia, 1988; 
Koga, 1997). After sample filtration, the membrane needs 
to be washed with a sterile 1% peptonated solution to avoid 
phenol residues into the culture medium, which might cause 
a false negative result. The transference of the membrane 
into the culture medium may be performed using a sterile 
clamp. The division of the membrane in two pieces for using 
with different culture mediums decreases the costs of the test 
and is optional. In case of the presence of microorganisms in 
the sample, they will be retained in the membrane and back 
to grow after incubation in enriched mediums and proper 
temperature and time (Fracalanzza, 2005).
The advantages of this method include: the non-
carrying of inactivating agents and/or preservatives to the 
culture medium, and specially, the possibility of testing 
injectables with large volume content (<5 liters), leading 
to a higher statistical representativeness compared to the 
direct method. Disadvantages include: high cost process 
and product manipulation, training requirement and sam-
ple limitation, restriction to products that are solubilized 
or in suspension. Table IV compares the advantages and 
disadvantages of the direct and indirect inoculation me-
thods based on different factors.
In VBI, all sterility tests are performed using the 
membrane filtration (indirect) method. The only excep-
tion is in microbiological trial of equine plasmas, when 
direct method is used, due to the high fibrin level that 
rapidly saturate the filtering member and the absence of 
preservatives. 
Culture conditions
Before performing the test, the viable residual 
contaminant or the product recontamination agents are 
unknown for the technician/analyst. Therefore, the selec-
tion of the culture medium is important, as it should offer 
ideal conditions for different microorganisms growth, 
fulfilling also their nutritional demanding (Bugno, 2001). 
The current pharmaceutical regulations determine 
the liquid culture medium use for promoting bacteria, 
TABLE IV - Comparison of direct inoculation and indirect (membrane filtering) methods 
 
Factor Direct Inoculation Indirect - Membrane Filtering 
Sensitivity Low High
Precision Low High
Indication (Volume) Suitable for small volumes (<100 mL) Suitable for bigger volumes (>100 mL)
Use in products with growth inhibitors Not suitable Suitable if inhibitors eliminated in rinsing step
Performance Fast and easy Slow and special equipment demands
Manipulation Low High (more training)
Cost Low High
Source: Fracalanzza, 2005.
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fungi and yeast growth. Thus, the minimum required 
is the use of two types of enriched culture medium that 
allow growth of the highest number of contaminants, as 
many as possible.
The international and national pharmacopeias 
indicate the use of thioglycolate broth containing resar-
zurine, which promotes growth of anaerobic, mesophilic 
aerobic and microaerophile bacteria when incubated at 
30-35 ºC; and casein-soy broth for detection of yeasts and 
psychrophile aerobic microorganisms after incubation 
in 20-25 ºC. The minimum volume necessary is 100mL 
for both medium culture and this protocol is adopted by 
VBI (Vital Brasil Institute, 2005 2006c).
The professed time for culture medium incubation 
is of 14 days (Brazilian Pharmacopeia, 1988; European 
Pharmacopeia, 2007; British Pharmacopoeia, 2008; Uni-
ted States Pharmacopeia, 2008). This increase of time is 
an improvement of the method as it allows the detection 
of slow growth microorganisms and those “stressed” by 
sterilizing process exposition or antimicrobials present 
in the product (Pedroso, Allil, 1998).
Data Analysis
A representative sample of a lot only fulfill the 
requirements of the sterility test when no microorganism 
growth is detected macroscopically in liquid (turbidity) 
or solid (colonies) medium after culture during 14 days 
(Fracalanzza, 2005; Vital Brazil Institute, 2005 and 
2006c). 
Overall the acceptance criteria of different regu-
lations are similar. According to rule nº 176, adopted 
by VBI, if there is no detection of microorganisms in 
the medium on the original test, the lot is considered as 
sterile and approved (Brasil, 1996). In contrast, if any 
microorganism is detected in the medium, a re-test is 
performed to assure that the contamination is from the 
product and not from the test manipulation. If the first 
re-test is positive, the antisera lot is disapproved whereas 
if it is negative, a second test is performed with double 
of samples. If the result is negative once more, the lot is 
approved whereas if a microorganism growth is detected, 
the lot is disapproved (Table V). 
The Brazilian Pharmacopeia still allows another 
possibility if the contamination persists in the first re-
test. On that case, the microorganisms isolated in the two 
occasions (initial test and first re-test) should be compa-
red. If they are the same contaminant, the lot is direct 
disapproved but if they are different, a second re-test 
may be performed using the double number of samples. 
If the contamination is not detected the lot should be 
approved (Table VI).
TABLE V - Interpretation of sterility test data according to rule nº 176
Class
evaluation
Test (0, 4 √ N) 1º Re-test (0, 4 √ N) 2º Re-test (0, 8 √ N) Final 
A negative growth - - Satisfactory
B positive growth negative growth negative growth Satisfactory *
C positive growth negative growth positive growth Unsatisfactory **
D positive growth positive growth - Unsatisfactory***
N= total number of vials from the lot. Source: Brazil, 1996.
TABLE VI - Interpretation of the sterility test data
Class
Original Test 
Sampling= (0.4 √ N)
1º Re-test 
Sampling = (0.4 √ N)
2º Re-test 
Sampling = (0.8 √ N)
Final Evaluation
A negative growth - - Satisfactory
B positive growth negative growth - Satisfactory
C positive growth positive growth - Unsatisfactory *
D positive growth positive growth negative growth Satisfactory **
E positive growth positive growth positive growth Unsatisfactory***
N= total number of vials from the lot; * Same microorganism detected in the original test and first re-test; ** Different 
microorganisms isolated in the original test, first re-test and negative second re-test; *** Contamination in the three tests, even by 
different microorganisms. Source: Brazil, 1996
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The validation and its applicability in 
antiophidian sera manufacturing process
Incidents reported in the 70´s decade about septice-
mia and deaths due to the parenteral use of contaminated 
material revealed the necessity of improvement of the 
current sterility tests, to assure the quality, safety, and 
efficiency of the product. On that purpose the monitoring 
of the whole manufacturing process and the validation of 
all steps including the sterility test became mandatory for 
sterile product manufacturing (Bugno, 2001).
According to the RDC nº 210 and RDC nº 899 
(Brasil, 2003b and c), the validation may be defined as 
a documented act, which assures that any procedure, 
process, equipment, material, operation or system, really 
leads to the expected results. Due to the statistical limi-
tations of the sterility test, it is necessary to use validated 
assays that present sensibility, accuracy, reproducibility 
and no false results caused by external factors. Besides, 
all installations and parameters such as the bacteriostatic 
and fungistatic effects of the preservative system should 
be previously qualified (Denyer, Baird, 2006). Simulta-
neously the determination of the contamination and of the 
operational conditions of the clean room where the assay 
is performed also contributes to assure the validity of the 
assay. The chapter 1208 of the American Pharmacopeia 
Sterility testing - Validation of isolator systems is a guideli-
ne for validation of the isolation system used in the sterility 
test. This system allows to eliminate the bioburden in the 
controlled environment where is performed the analysis. 
The validation of the sterility test per se is presented in 
chapter 71 Sterility tests.
Environment qualification
It certifies and monitors the assay performance 
physical area including regarding the microorganisms 
presence (Pinto, Kanako, Ohara, 2003). The air sampling 
should be performed in specific points during the area 
normal activity through static sampling or air collectors. 
The same parameters should be evaluated in the test area. 
The air microbiological quality and the amount of suspen-
ded particles should be monitored by both plating and air 
centrifuge samplers and compared to US Federal Standard 
recommended limits (Table VII) (INCQS/Fiocruz, 2005a 
e 2006b). 
Air collecting sampling is performed by using 
equipments with air suctioning filters for retain eventual 
particles. The filters are placed in the culture medium 
for monitoring the microbial growth and quantifying 
the amount of particle per volume of filtered air. On that 
purpose the Colonies Forming Units (CFU) amount are 
determined after plate incubation for 5 days. The surface 
microbial control may be performed by using Rodac® 
plates (Peixoto, Oda, 1984b; Halls, 2004). 
Workers qualification
The operators are potential causes of contamination 
during assay. Since the microorganisms are always asso-
ciated to skin, hair and nails, among others, the operator 
should receive specific training to guarantee the assay suc-
cess (Halls, 2004). The operators should be aware of the 
importance of the assay and of their own role in immuno-
biological quality control. An intensive training program 
with the inclusion of asepsis and biosafety concepts is a 
fundamental resource for reducing false-positive results 
(from operation contamination) that should not exceed 
2%. Operators with infectious disease may not perform 
sterility assays. Operational control also involves using 
proper clothes, equipments and sterile materials (INCQS/
Fiocruz, 2005b).
Validation
It must include the analysis of sterility, the culture 
medium growth features, and of the preservative remo-
val efficiency from the product during the washing step 
using peptone solution. Most of the preservative are from 
phenolic derivatives class. VBI uses 0.35% phenol in the 
antiophidian sera preparation (Brazilian Pharmacopeia, 
2003). The preservative are necessary to maintain the phar-
macologic integrity and should present specific features 
such as: a) no interaction with the active drug, b) potent 
and large spectrum antimicrobial profile that is easily blo-
cked or attenuated when necessary, c) atoxic in the allowed 
concentration, and d) stable and soluble (Pimenta, 2005).
The evaluation of the preservatives/antimicrobial 
presence in the product determines the bacteriostatic and 
antifungal effects. This intends to prevent false-negative 
results and establish the best membrane rinsing system to 
be used in the end of each filtration. It consists in inocu-
















A 1 1 1
B 10 5 5
C 100 50 25
D 200 100 50
Available in: http:// www.morfield.co.uk.
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lating the final rinsing into proper culture medium with 
proper microorganisms. After adequate period of time and 
temperature, the microbial growth observed should reveal 
the complete removal of residual inactivators as well as of 
preservatives and antimicrobials (Pedroso, Allil, 1998).
Due to the specific features of the sterility test and 
the rigid criteria used for the interpretation of the results, 
it is necessary to confirm the capacity of the culture me-
dium of allowing recovery and growth of even a reduced 
number of viable microorganisms. Therefore, the sterility 
test must be performed for each lot of prepared medium. 
It consists of inoculation of 10 to 100 UFC of reference-
strains at proper temperature for at least 7 days to detect 
the microbial growth (positive control) (Table VIII). In 
addition the sterility of the medium should be confirmed 
by performing the negative control (medium not inocu-
lated) of the sterility test (Brazilian Pharmacopeia, 1988; 
Fracalanzza, 2005; United States Pharmacopeia, 2008). 
Assay invalidation
The sterility assay is invalidated due to: a) unsa-
tisfactory microbiological environment monitoring, b) 
human flaw on analysis procedure, c) microbial growth in 
negative control and/or absence of growth in the positive 
control, and d) preservative interference in the test result. 
In case of invalidation, the test must be performed once 
more using the same number of sample of the original test, 
besides preventive actions for controlling it (United States 
Pharmacopeia, 2008).
Pyrogen Control
A particular attention to pyrogen presence should be 
taken for producing injectables. The detection of pyrogen 
agents may be difficult in in vivo assays in case of immu-
nobiologics and antisera that may generate a fever reac-
tion when administered, due to the iatrogenic feature. On 
that case, the alternative suggested by RDC 249 (Brasil, 
2005) is the in vitro test. The detection is based on the co-
agulation of a proteinic homogenate from horseshoe crab 
hemolymph (Limulus polyphemus) in presence of gram-
negative bacteria LPS (Pinto, Kanako, Ohara, 2003). It is 
interesting to notice that this sensible assay must fulfill 
extremely restricted validation criteria, which reduces the 
high incidence of false-positive or negative results. The 
test was accepted by FDA in 1982 and predicts the use of 
a pre-validate kit that include lyophilized pyrogen reagent 
(proteinic homogenate from hemolymph), lyophilized 
reference Escherichia coli endotoxin (in international 
unities) and pyrogen-free water (BET-bacterial endotoxin 
free-water). Once properly reconstituted with BET water, 
the initial and essential procedure for the execution of the 
test with several samples involves negative and positive 
controls.
Positive control
It is performed by incubating 0.1 mL of pyrogen 
reagent plus 0.1 mL of diluted endotoxin (as described 
by the kit) in a pyrogen-free test tube for 30 min at 37 oC. 
Expected result: jellification.
Sample positive control
It is performed by incubating 0.1 mL of pyrogen 
reagent plus 0.1 mL of diluted endotoxin (as described by 
the kit) and 0.1 mL of sample in a pyrogen-free test tube 
for 30 min at 37 oC. Expected result: jellification.
Negative control
It is performed by incubating 0.1 mL of pyrogen 
reagent and 0.1 mL of BET water in a pyrogen-free test 
tube for 30 min at 37 oC. Expected result: absence of 
jellification.
It is interesting to observe the sample positive 
control. If there is no jellification, the interference (inhi-
bitor) presence is implied. Several authors reported the 
interference of calcium chelators such as EDTA (used as 
TABLE VIII - Reference strains used in culture medium validation
 
Microorganism Respiratory Metabolism Reference Culture Medium 
Bacillus subtilis / Kocuria Rhizophila 
ATCC 6633
Aerobic Tioglicolate or Casein-Soy
Micrococcus luteus ATCC 9341 Aerobic Tioglicolate
Bacterioides vulgatus ATCC 8482 Anaerobic Tioglicolate
Clostridium sporogenes ATCC 11437 Anaerobic Tioglicolate
Candida albicans ATCC 10231 Aerobic Casein-soy
Source: Fracalanzza, 2005.
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preservative) that avoid the jellification reaction (Cooper, 
Weary, Jordan, 1997). If not solved by the interference 
elimination, the inhibition of the positive reaction by the 
sample avoids the use of in vitro assays for endotoxin 
monitoring and detection in injectable preparations. If the 
sample does not cause iatrogenic fever reaction, in vivo 
assays may be used as alternative method (Pinto, Kanako, 
Ohara, 2003).
FINAL CONSIDERATIONS
Absence of microorganisms and consistent results 
in the sterility and pyrogenic tests are some of the goals to 
be reached for antiophidian sera final products. Therefore 
the control performed during the manufacturing of these 
products significantly contributes to reach these goals. The 
insertion of these controls in real time and direct coupled 
to the manufacturing process reinforced the applicability 
of the parametric release concept for assuring the sterility 
of the final product.
In case of detecting microbial contamination during 
plasma processing and mainly in the sera produced at large 
scale, the product may be reprocessed and submitted to 
a new sterilizing filtration process. This following from 
the raw material acquisition till the filling of the product, 
allow many corrective actions to assure the quality of 
antiophidian sera supplied for Brazilian Health Minister.
The sterility test is: a) part of the microbiological 
control of the antiophidian sera production, b) an impor-
tant assay for the institutions involved on producing these 
sera and c) a target for continue studying and improving of 
its efficacy (Brasil, 1996). In fact, the level of microbio-
logical reliability of sterile products increased due to the 
several productive advances including the improvement 
of methodologies for contaminants detection and the 
application of more restricted validation criteria (Denyer, 
Baird, 2006).
The severity in the interpretation of the results based 
on a regulatory literature is also important to avoid false-
negatives (low level of undetected contamination) or false-
positives (rejection of a lot that may be considered sterile 
but that failed in the sterility test) results. Both cases com-
promise months of works due to: a) the reprocess of the 
product, b) lost of a false-positive lot, c) re-test needing, 
and d) processing for identifying the contamination origin 
that are always time and workers consuming (Pedroso, 
Allil, 1998; Fracalanzza, 2005).
All analyzed Pharmacopeias indicated the use of 
0.45 mm-membrane in the sterility test. These monogra-
phs involve all sterile parenteral and immunobiologics 
products that, besides the hyperimmune sera, also include 
more dense vaccines that contain adjuvants for which 0.22 
mm-membranes are not appropriate. As antiophidian sera 
are easily filtrated in 0.22 mm-membranes, VBI correctly 
choose these membranes for having a safer profile of 
preparation (Brazilian Pharmacopeia, 1988; European 
Pharmacopeia, 2007; British Pharmacopoeia, 2008; Uni-
ted States Pharmacopeia, 2008).
The validation of all processes that guarantee the 
sterility in all aspects including environmental, operational 
and methodological are considered important as contribu-
tes to obtain satisfactory and safety results. Importantly 
there are intrinsic limitations of the sterility test despite 
the methodological advances developed during all these 
years. Probably the most limiting factor is the statistical 
parameter of the assay. As this test is destructive, not all 
flasks or pack are submitted, which generated unsureness 
about the sterility of the whole lot. Therefore the sample 
selection criteria are always in debate. Currently the test 
detects high contamination levels whereas the ability of 
detecting rare contamination is limited unless the number 
of samples is high (Peixoto, Oda, 1984; Pinto, Kaneko, 
Ohara, 2003). 
Another limitation of the sterility test is related to not 
allowing growth of all types of microorganisms. The test 
provides perfect conditions for bacteria, fungi and yeast 
development but still not for virus. Even bacteria and fun-
gi, the negative results are extended values (Denyer, Baird, 
2006). Besides two culture media may be not sufficient to 
fulfill the nutritional requirements of some specific mi-
croorganisms, and/or the incubation temperature may not 
allow the development of all psychrophile and thermophile 
microorganism (Bugno, 2001). 
Despite of allowing the recovery of microorganisms 
for a period of 14h, the sterility test may also fail due to 
the absence of a mechanism of recovery of the microbial 
cells subletally affected by sterilizing processes or by the 
contact of antimicrobials/preservatives added to the an-
tiophidian sera. Therefore the absence of microorganism 
growth detected by a sterility test does not mean 100% 
assure the complete product sterility (Bugno, 2001; Pe-
droso, Allil, 1998).
In the manufacturing of sterilizing filtration submitted 
products, the applicability of the parametric release is con-
troversial. The Brazilian legislation already accepts the data 
of physic chemistry and potency controls performed with 
antiophidian sera produced in large scale. The exceptions 
are the sterility and pyrogen tests as they can be altered 
during the filling step. As alternative, it may be considered 
the parameters observed in the sterility ensuring system as 
base for supporting the final sterility of the product.
In addition, the Process Analytical Technology 
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(PAT) that associates control parameters (i.e. conductivity, 
total organic carbon value in the water production line for 
injectables products and suspended particles, temperature 
and humidity of the manufacturing environment) allowed 
not only the statistical analysis of the results in real time 
as well as the control system that performs adjustments 
to get the perfect work condition (Guidance for industry 
- PAT, 2003). On that way the reliability of the sterility 
test reaches the requested levels for assuring the safety 
of antisera and vaccines produced to the final consumer. 
Therefore the sterility test is a reference assay that 
should be considered among several controls measure-
ments to decide if a sterile product fulfills the legislation 
requirements. Due to the limitations, the Good Manu-
facture Practices should be used by any institution that 
produces sterile medicaments and immunobiologicals (i.e. 
VBI), searching continuously for quality excellence and 
consequently safety for these products. This review hopes 
to contribute for the development of new microbial detec-
tion methods comparable or even better than the current 
ones to promote a major efficiency in the microbiological 
control of these products, with fulfillment of the current 
legislation and of the consumers expectation.
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